Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease

The Lancet Respiratory Medicine

Volumn 4, Issue 2, 2016, Pages 138-148

  MacDonald, Martin I ^a   Shafuddin, Eskandarain ^b,c   King, Paul T ^a   Chang, Catherina L ^b   Bardin, Philip G ^a   Hancox, Robert J ^b,c  

^a MONASH UNIVERSITY   (Australia)

^b WAIKATO HOSPITAL   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; PROTHROMBIN; TROPONIN; TUMOR NECROSIS FACTOR ALPHA;

BIOCHEMISTRY; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DISEASE EXACERBATION; ELECTROCARDIOGRAPHY; EMPHYSEMA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HUMAN; HYPOXEMIA; INFLAMMATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; TACHYCARDIA; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; CARDIOVASCULAR DISEASES; DISEASE COURSE; HEART DISEASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HEART DISEASES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84958121472     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00509-3     Document Type: Review

References (111)

1. Mullerova H, Agusti A, Erqou S, Mapel DW Cardiovascular comorbidity in COPD: systematic literature review. Chest 2013, 144:1163-1178.
2. Patel AR, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest 2012, 141:851-857.
3. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT Does this dyspneic patient in the emergency department have congestive heart failure?. JAMA 2005, 294:1944-1956.
4. Brekke PH, Omland T, Smith P, Soyseth V Underdiagnosis of myocardial infarction in COPD-cardiac infarction injury score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008, 102:1243-1247.
5. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996, 154:959-967.
6. Pavasini R, d'Ascenzo F, Campo G, et al. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Cardiol 2015, 191:187-193.
7. McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012, 39:1097-1103.
8. Harvey MG, Hancox RJ Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emerg Med Australas 2004, 16:212-215.
9. Soyseth V, Bhatnagar R, Holmedahl NH, et al. Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T. Heart 2013, 99:122-126.
10. Hoiseth AD, Omland T, Hagve TA, Brekke PH, Soyseth V Determinants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. BMC Pulm Med 2012, 12:22.
11. Abroug F, Ouanes-Besbes L, Nciri N, et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006, 174:990-996.
12. Ouanes I, Jalloul F, Ayed S, et al. N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction. Respirology 2012, 17:660-666.
13. Patel AR, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 188:1091-1099.
14. Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008, 133:1088-1094.
15. Gariani K, Delabays A, Perneger TV, Agoritsas T Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Swiss Med Weekly 2011, 141:w13298.
16. Nishimura K, Nishimura T, Onishi K, Oga T, Hasegawa Y, Jones PW Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014, 9:155-162.
17. Escande W, Duva Pentiah A, Coisne A, et al. Left ventricular myocardial performance index predicts poor outcome during COPD exacerbation. Int J Cardiol 2014, 173:575-579.
18. Hoiseth AD, Omland T, Hagve TA, Brekke PH, Soyseth V NT-proBNP independently predicts long term mortality after acute exacerbation of COPD-prospective cohort study. Respir Res 2012, 13:97.
19. Medina AM, Marteles MS, Saiz EB, et al. Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases. Eur J Intern Med 2011, 22:167-171.
20. Macchia A, Monte S, Romero M, D'Ettorre A, Tognoni G The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail 2007, 9:942-948.
21. Stefan MS, Bannuru RR, Lessard D, Gore JM, Lindenauer PK, Goldberg RJ The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a 10-year retrospective observational study. Chest 2012, 141:1441-1448.
22. Soriano JB, Rigo F, Guerrero D, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest 2010, 137:333-340.
23. Lange P, Nyboe J, Jensen G, Schnohr P, Appleyard M Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. Eur Respir J 1991, 4:1080-1087.
24. Kannel WB, Hubert H, Lew EA Vital capacity as a predictor of cardiovascular disease: the Framingham study. Am Heart J 1983, 105:311-315.
25. Mannino DM, Doherty DE, Sonia Buist A Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the atherosclerosis risk in communities (ARIC) study. Respir Med 2006, 100:115-122.
26. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA, Committee TCE Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007, 62:411-415.
27. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012, 39:51-58.
28. Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009, 11:1182-1188.
29. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006, 16:63-70.
30. Agabiti N, Belleudi V, Davoli M, et al. Profiling hospital performance to monitor the quality of care: the case of COPD. Eur Respir J 2010, 35:1031-1038.
31. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest 2002, 121:1441-1448.
32. Almagro P, Cabrera FJ, Diez-Manglano J, et al. Comorbidome and short-term prognosis in hospitalised COPD patients: the ESMI study. Eur Respir J 2015, 46:850-853.
33. Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J 2008, 31:563-570.
34. Bustamante-Fermosel A, De Miguel-Yanes JM, Duffort-Falco M, Munoz J Mortality-related factors after hospitalization for acute exacerbation of chronic obstructive pulmonary disease: the burden of clinical features. Am J Emerg Med 2007, 25:515-522.
35. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011, 66:764-768.
36. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008, 63:301-305.
37. Fruchter O, Yigla M Cardiac troponin-predicts long-term mortality in chronic obstructive pulmonary disease. COPD 2009, 6:155-161.
38. Fuso L, Incalzi RA, Pistelli R, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995, 98:272-277.
39. Harrison MT, Short P, Williamson PA, Singanayagam A, Chalmers JD, Schembri S Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy?. Thorax 2014, 69:609-615.
40. Hasegawa W, Yamauchi Y, Yasunaga H, et al. Factors affecting mortality following emergency admission for chronic obstructive pulmonary disease. BMC Pulm Med 2014, 14:151.
41. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997, 10:2794-2800.
42. Lainscak M, von Haehling S, Doehner W, et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle 2011, 2:81-86.
43. Lindenauer PK, Grosso LM, Wang C, et al. Development, validation, and results of a risk-standardized measure of hospital 30-day mortality for patients with exacerbation of chronic obstructive pulmonary disease. J Hosp Med 2013, 8:428-435.
44. Marcun R, Sustic A, Brguljan PM, et al. Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol 2012, 161:156-159.
45. McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007, 132:1748-1755.
46. Raurich JM, Perez J, Ibanez J, Roig S, Batle S In-hospital and 2-year survival of patients treated with mechanical ventilation for acute exacerbation of COPD. Archivos de Bronconeumologia 2004, 40:295-300.
47. Roberts CM, Stone RA, Lowe D, Pursey NA, Buckingham RJ Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations. COPD 2011, 8:354-361.
48. Slenter RH, Sprooten RT, Kotz D, Wesseling G, Wouters EF, Rohde GG Predictors of 1-year mortality at hospital admission for acute exacerbations of chronic obstructive pulmonary disease. Respiration 2013, 85:15-26.
49. Soyseth V, Brekke PH, Smith P, Omland T Statin use is associated with reduced mortality in COPD. Eur Respir J 2007, 29:279-283.
50. Steer J, Gibson J, Bourke SC The DECAF score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012, 67:970-976.
51. Stiell IG, Clement CM, Aaron SD, et al. Clinical characteristics associated with adverse events in patients with exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. CMAJ 2014, 186:E193-E204.
52. Tabak YP, Sun X, Johannes RS, Hyde L, Shorr AF, Lindenauer PK Development and validation of a mortality risk-adjustment model for patients hospitalized for exacerbations of chronic obstructive pulmonary disease. Med Care 2013, 51:597-605.
53. Terzano C, Conti V, Di Stefano F, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung 2010, 188:321-329.
54. Wildman MJ, Sanderson C, Groves J, et al. Predicting mortality for patients with exacerbations of COPD and Asthma in the COPD and asthma outcome study (CAOS). QJM 2009, 102:389-399.
55. Baillard C, Boussarsar M, Fosse JP, et al. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2003, 29:584-589.
56. Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V Determinants of cardiac troponin T elevation in COPD exacerbation-cross-sectional study. BMC Pulm Med 2009, 9:35.
57. Campo G, Pavasini R, Malagu M, et al. Relationship between troponin elevation, cardiovascular history and adverse events in patients with acute exacerbation of COPD. COPD 2015, 12:560-567.
58. Gale CP, White JE, Hunter A, et al. Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical and echocardiographic assessment. J Cardiovasc Med (Hagerstown) 2011, 12:613-618.
59. Hoiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Soyseth V Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 2011, 66:775-781.
60. Hoiseth AD, Neukamm A, Hagve TA, Omland T, Brekke PH, Soyseth V The clinical value of serial measurement of high-sensitivity cardiac troponin T in acute exacerbations of chronic obstructive pulmonary disease. Open Heart 2014, 1:e000001.
61. Inoue Y, Kawayama T, Iwanaga T, Aizawa H High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009, 48:503-512.
62. Kanat F, Vatansev H, Teke T Diuretics, plasma brain natriuretic peptide and chronic obstructive pulmonary disease. Neth J Med 2007, 65:296-300.
63. Kelly AM, Klim S Is elevated troponin associated with in-hospital mortality in emergency department patients admitted with chronic obstructive pulmonary disease?. Eur J Emerg Med 2013, 20:54-57.
64. Martins CS, Rodrigues MJ, Miranda VP, Nunes JP Prognostic value of cardiac troponin I in patients with COPD acute exacerbation. Neth J Med 2009, 67:341-349.
65. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003, 10:198-204.
66. Sanchez-Marteles M, Cecilio-Irazola A, Vano-Sanchis D, Nuviala-Mateo R, Serrano-Martinez S, Perez-Calvo JJ NT-proBNP in chronic obstructive pulmonary disease patients. An Sist Sanit Navar 2009, 32:235-241. (in Spanish).
67. Sanchez-Marteles M, Molina Medina A, Bermejo Saiz E, Ruiz Laiglesia F, Nieto Rodriguez JA, Perez-Calvo JI Prognostic value of NT-proBNP in chronic pulmonary disease exacerbation. Medicina Clinica 2010, 135:441-446. (in Spanish).
68. Yang HH, Zhou Y Effect of invasive and non-invasive positive pressure ventilation on plasma brain natriuretic peptide in patients with chronic obstructive pulmonary disease and severe respiratory failure. Nan fang yi ke da xue xue bao 2010, 30:2377-2379. (in Chinese).
69. Youssef ARI, Hassan ASA, El-Ghamry R, Ahmed AE Serum troponin-as a prognostic marker in acute exacerbated chronic obstructive pulmonary disease patients. Egypt J Chest Dis Tuberculosis 2013, 62:549-555.
70. Alcalai R, Planer D, Culhaoglu A, Osman A, Pollak A, Lotan C Acute coronary syndrome vs nonspecific troponin elevation: clinical predictors and survival analysis. Arch Intern Med 2007, 167:276-281.
71. Neukamm AM, Hoiseth AD, Hagve TA, Soyseth V, Omland T High-sensitivity cardiac troponin T levels are increased in stable COPD. Heart 2013, 99:382-387.
72. Anderson WJ, Lipworth BJ, Rekhraj S, Struthers AD, George J Left ventricular hypertrophy in COPD without hypoxemia: the elephant in the room?. Chest 2013, 143:91-97.
73. Giannitsis E, Muller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000, 102:211-217.
74. Daniels LB, Maisel AS Natriuretic peptides. J Am Coll Cardiol 2007, 50:2357-2368.
75. Pesaro AE, Katz M, Caixeta A, et al. Prognostic value of serial brain natriuretic peptide measurements in patients with acute myocardial infarction. Cardiol 2015, 131:116-121.
76. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
77. Clayton TC, Thompson M, Meade TW Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008, 29:96-103.
78. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010, 137:1091-1097.
79. Chang CL, Mills GD, Karalus NC, et al. Biomarkers of cardiac dysfunction and mortality from community-acquired pneumonia in adults. PloS One 2013, 8:e62612.
80. Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013, 68:670-676.
81. Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011, 66:769-774.
82. Malerba M, Clini E, Malagola M, Avanzi GC Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. Expert Rev Hematol 2013, 6:475-483.
83. Boussuges A, Pinet C, Molenat F, et al. Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and doppler study. Am J Respir Crit Care Med 2000, 162:670-675.
84. Jorgensen K, Muller MF, Nel J, Upton RN, Houltz E, Ricksten SE Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study. Chest 2007, 131:1050-1057.
85. Salpeter SR, Ormiston TM, Salpeter EE Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004, 125:2309-2321.
86. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003, 123:1964-1969.
87. McDevitt DG, Shanks RG, Swanton JG Further observations on the cardiotoxicity of isoprenaline during hypoxia. Br J Pharmacol 1974, 50:335-344.
88. Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001, 250:327-341.
89. Rajwani A, Adam Z, Hall JA Bronchogenic stress cardiomyopathy: a case series. Cardiol 2015, 130:106-111.
90. Madias JE Bronchogenic stress cardiomyopathy, a subset of Takotsubo syndrome. Cardiol 2015, 131:160.
91. Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012, 367:913-921.
92. Acikel M, Kose N, Aribas A, et al. The effect of pulmonary hypertension on left ventricular diastolic function in chronic obstructive lung disease: a tissue doppler imaging and right cardiac catheterization study. Clin Cardiol 2010, 33:E13-E18.
93. MacNee W, Xue QF, Hannan WJ, Flenley DC, Adie CJ, Muir AL Assessment by radionuclide angiography of right and left ventricular function in chronic bronchitis and emphysema. Thorax 1983, 38:494-500.
94. Van Gestel AJ, Steier J Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD). J Thoracic Dis 2010, 2:215-222.
95. Hublitz UF, Shapiro JH Atypical pulmonary patterns of congestive failure in chronic lung disease. The influence of pre-existing disease on the appearance and distribution of pulmonary edema. Radiology 1969, 93:995-1006.
96. Kumar A, Patton DJ, Friedrich MG The emerging clinical role of cardiovascular magnetic resonance imaging. Can J Cardiol 2010, 26:313-322.
97. Domanski MJ, Krause-Steinrauf H, Massie BM, et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 2003, 9:354-363.
98. Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 2009, 11:684-690.
99. Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J 2010, 40:193-200.
100. Chhabra SK, Gupta M, Ramaswamy S, Dash DJ, Bansal V, Deepak KK Cardiac sympathetic dominance and systemic inflammation in COPD. COPD 2015, 12:552-559.
101. Jensen MT, Suadicani P, Hein HO, Gyntelberg F Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen male study. Heart 2013, 99:882-887.
102. Du Q, Sun Y, Ding N, Lu L, Chen Y Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PloS One 2014, 9:e113048.
103. Bhatt SP, Wells JM, Kinney GL, et al. Beta-blockers are associated with a reduction in COPD exacerbations. Thorax 2015, published online Aug 17. 10.1136/thoraxjnl-2015-207251.
104. Cazzola M, Calzetta L, Matera MG, Muscoli S, Rogliani P, Romeo F Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respir Med 2015, 109:1019-1025.
105. Riccioni G Ivabradine: the hope for a good treatment of ischemic heart disease. Curr Med Chem 2013, 20:1817-1823.
106. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. New Engl J Med 2014, 370:2201-2210.
107. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009, 10:45.
108. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47:2554-2560.
109. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2001-2007. MERIT-HF Study Group.
110. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13. CIBIS-II investigators and committees.
111. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986, 328:57-66. ISIS-(First International Study of Infarct Survival) Collaborative Group.